GlassScriptPhysician profile
Reneallia Bennett
NPI 1023362886
$3,742.32
in general payments reported to CMS, 2019-2025
30 companies · $401 in 2025
The $401 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $522 · 2022: $837 · 2023: $1,119 · 2024: $864 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,350 · Entertainment: $33.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,350.36 |
| Entertainment | $33.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $968.26 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $359.44 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $358.48 | 2021-2025 | Prolia, Evenity, Repatha |
| Abbvie INC. | $273.25 | 2021-2023 | |
| Novo Nordisk INC | $225.45 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $205.37 | 2021-2025 | |
| Lilly USA, LLC | $203.12 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.44 | 2021-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $111.17 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $111.10 | 2022-2023 | |
| Lucid Diagnostics INC. | $101.45 | 2022-2024 | |
| Astellas Pharma US INC | $95.01 | 2023-2024 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $85.83 | 2021-2022 | |
| Exact Sciences Corporation | $62.52 | 2023-2024 | Cologuard Collection Kit |
| Neurocrine Biosciences, INC. | $60.25 | 2023-2024 | Ingrezza |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $48.32 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $43.32 | 2025 | Abilify Asimtufii, Abilify Maintena |
| Indivior INC. | $43.06 | 2024 | Sublocade |
| Mylan Specialty L.P. | $40.01 | 2022-2023 | Yupelri |
| Optos, INC. | $33.68 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Merck Sharp & Dohme LLC | $26.47 | 2021-2023 | Belsomra |
| Nestle Healthcare Nutrition INC. | $23.44 | 2023 | |
| Xeris Pharmaceuticals, INC. | $22.18 | 2025 | Recorlev |
| Teva Pharmaceuticals USA, INC. | $20.37 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $19.79 | 2021 | |
| Bardy Diagnostics, INC. | $17.18 | 2022 | |
| Collegium Pharmaceutical, INC. | $16.91 | 2023 | Xtampza |
| Janssen Pharmaceuticals, INC | $16.22 | 2023 | Xarelto |
| Currax Pharmaceuticals LLC | $13.69 | 2024 | Contrave, Onzetra Xsail |
| Novartis Pharmaceuticals Corporation | $13.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reneallia Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.